Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 2/20 | 0.42 |
| ▸ | KDM1B | Q8NB78 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | DPP4 | P27487 | 4/20 | 0.36 |
| ▸ | HCAR2 | Q8TDS4 | 2/20 | 0.35 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.34 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.34 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.34 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.34 |
| ▸ | HTR2A | P28223 | 1/20 | 0.34 |
| ▸ | HTR2C | P28335 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tert-Butyl Formate SCHEMBL28305239 | 0.87 | CA1 (0.34) | KDM1AKDM1BKMT2AMEN1NPC1 | |
| SCHEMBL21319503 | 0.78 | CA1 (0.33) | KMT2AMEN1CA1CA2 | |
| SCHEMBL2581206 | 0.75 | HTR2A (0.36) | KDM1ACHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL2577948 | 0.75 | HTR2A (0.36) | KDM1ACHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL426443 | 0.73 | KDM1A (0.53) | KDM1AKDM1BKMT2AMEN1NPC1 | |
| SCHEMBL29115960 | 0.71 | KDM1A (0.40) | KDM1AKDM1BKMT2AMEN1NPC1 | |
| SCHEMBL6794027 | 0.70 | KDM1A (0.46) | KDM1AKDM1BKMT2AMEN1NPC1 | |
| SCHEMBL18606766 | 0.70 | KDM1A (0.46) | KDM1AKDM1BKMT2AMEN1NPC1 | |
| SCHEMBL31478473 | 0.70 | MEN1 (0.44) | KDM1AKDM1BKMT2AMEN1NPC1 | |
| SCHEMBL21319531 | 0.70 | KDM1A (0.46) | KDM1AKDM1BKMT2AMEN1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3533796-B1 | AMINO PYRAZOLOPYRIMIDINE COMPOUND USED AS NEUROTROPHIC FACTOR TYROSINE KINASE RECEPTOR INHIBITOR | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO LTD (CN) | 2021-09-29 | — | — | EP | disclosed |
| EP-3533796-B1 | AMINO PYRAZOLOPYRIMIDINE COMPOUND USED AS NEUROTROPHIC FACTOR TYROSINE KINASE RECEPTOR INHIBITOR | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO LTD (CN) | 2021-09-29 | — | — | EP | disclosed |
| US-10829492-B2 | Amino pyrazolopyrimidine compound used as neurotrophic factor tyrosine kinase receptor inhibitor | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2020-11-10 | — | — | US | disclosed |
| US-10829492-B2 | Amino pyrazolopyrimidine compound used as neurotrophic factor tyrosine kinase receptor inhibitor | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2020-11-10 | — | — | US | disclosed |
| CN-109890820-B | Aminopyrazolopyrimidine compounds as neurotrophin tyrosine kinase receptor inhibitors | 正大天晴药业集团股份有限公司 | 2020-11-03 | — | — | CN | disclosed |
| US-20190352306-A1 | AMINO PYRAZOLOPYRIMIDINE COMPOUND USED AS NEUROTROPHIC FACTOR TYROSINE KINASE RECEPTOR INHIBITOR | LIANYUNGANG RUNZHONG PHARMACEUTICAL CO., LTD. (CN) | 2019-11-21 | — | — | US | disclosed |
| US-20190352306-A1 | AMINO PYRAZOLOPYRIMIDINE COMPOUND USED AS NEUROTROPHIC FACTOR TYROSINE KINASE RECEPTOR INHIBITOR | LIANYUNGANG RUNZHONG PHARMACEUTICAL CO., LTD. (CN) | 2019-11-21 | — | — | US | disclosed |
| EP-3533796-A1 | AMINO PYRAZOLOPYRIMIDINE COMPOUND USED AS NEUROTROPHIC FACTOR TYROSINE KINASE RECEPTOR INHIBITOR | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CN) | 2019-09-04 | — | — | EP | disclosed |
| EP-3533796-A1 | AMINO PYRAZOLOPYRIMIDINE COMPOUND USED AS NEUROTROPHIC FACTOR TYROSINE KINASE RECEPTOR INHIBITOR | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CN) | 2019-09-04 | — | — | EP | disclosed |
| CN-108003161-A | Neurotrophic factor tyrosine kinase receptor inhibitor | 正大天晴药业集团股份有限公司 | 2018-05-08 | — | — | CN | disclosed |
| WO-2018077246-A1 | AMINO PYRAZOLOPYRIMIDINE COMPOUND USED AS NEUROTROPHIC FACTOR TYROSINE KINASE RECEPTOR INHIBITOR | 正大天晴药业集团股份有限公司 | 2018-05-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10829492-B2 | Amino pyrazolopyrimidine compound used as neurotrophic factor tyrosine kinase receptor inhibitor | NTRK2, BDNF, NTRK1 | KDM1A 3602/4885KDM1B 3623/4885KMT2A 2895/4885 |
| US-20190352306-A1 | AMINO PYRAZOLOPYRIMIDINE COMPOUND USED AS NEUROTROPHIC FACTOR TYROSINE KINASE RECEPTOR INHIBITOR | NTRK2, BDNF, NTRK1 | KDM1A 3602/4885KDM1B 3623/4885KMT2A 2895/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.